Skip to main content

Bolt Biotherapeutics, Inc.

BOLT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001641281

In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Bolt Biotherapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of BOLT: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders35140+6
Shares24.5M415.0K24.1M−1.34K (0.0%)
Value$25.5M$431.6K$27.0M+$1.93M (+7.7%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held Bolt Biotherapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to BOLT in Q4 2023
InstitutionSharesValue% of portfolio
Two Sigma Securities, LLC64,232$71.9K0.00%
Jane Street Group, LLC56,264$63.0K0.00%
XTX Topco Ltd19,152$21.4K0.00%
Prudential Financial Inc12,200$13.7K0.00%
Tower Research Capital LLC (TRC)8,236$9.22K0.00%
Advisor Group Holdings, Inc.3,978$4.46K0.00%
Citigroup Inc2,307$2.58K0.00%

Sold out (1)

Institutions that held Bolt Biotherapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of BOLT in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Federated Hermes, Inc.1,161$1.21K

Not filed for Q4 2023 yet (1)

Institutions that held Bolt Biotherapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding BOLT in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Hawkeye Capital Management, LLC415,039$431.6K